Results 181 to 190 of about 13,710,280 (250)
Environmental, Social, and Governance Information Disclosure: Who Discloses Wins?
Business Strategy and the Environment, EarlyView.ABSTRACT As Environmental, Social, and Governance (ESG) Information Disclosure (ESG‐ID) transitions from voluntary to mandatory disclosure, its drivers and impacts have become focal points of discussion. Existing research, however, lacks integration, which, in turn, has led to fragmented theoretical and practical insights.
Siqi Wang +3 more
wiley +1 more source
Business Strategy and the Environment, EarlyView.ABSTRACT The transition to a circular economy (CE) increasingly depends on circular ecosystems: networks of autonomous yet interdependent actors that must coordinate material, information, and value flows to narrow, slow, and close resource loops. This creates a governance problem: Circularity requires orchestration, yet no single actor can impose ...
Felix Carl Schultz +3 more
wiley +1 more source
Repair in the Circular Economy: From Fragmented Practices to Strategic Repair Capability
Business Strategy and the Environment, EarlyView.ABSTRACT Repair is central to the circular economy, yet research remains fragmented across product design, consumer behaviour, business models, community initiatives and policy, limiting understanding of how these dimensions interact to enable repair at scale.
Azar MahmoumGonbadi +2 more
wiley +1 more source
Techno‐Economic Assessment of Biomethane and Biohydrogen Production From Victorian Wheat Straw
Carbon Energy, EarlyView.Techno‐economic assessment of biomethane and biohydrogen production from Victorian wheat straw. Off‐grid renewable photovoltaic energy with a price down to 0.95 ¢/kWh was applied. Both approaches can make positive profits and negative carbon footprints.
Shuanglong Tan +7 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor +12 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai +12 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Real‐world evidence (RWE) derived from real‐world data (RWD) can complement randomized controlled trials (RCTs), yet the validity of RWD relative to RCT data remains insufficiently characterized. We obtained post hoc consent and linked individual participant data from the US‐based INVESTED trial (2016–2019) with Medicare fee‐for‐service claims (2012 ...
Hanseul Cho +12 more
wiley +1 more source
The Governance Gap: Democratizing Drug Development Through Decision Architecture
Clinical Pharmacology &Therapeutics, EarlyView.Drug development is most exposed to governance failure where it can least afford it, in global health. The field has more predictive power than at any point in its history and roughly the same failure rate it had a decade ago. We argue that this paradox persists because the field has invested heavily in prediction science while neglecting decision ...
Craig R. Rayner +16 more
wiley +1 more source
Corporate Social Responsibility and Environmental Management, EarlyView.ABSTRACT This study examines the relationship between artificial intelligence and both environmental and social sustainability practices in small and medium‐sized enterprises, with a specific focus on the moderating effects of implementation barriers relating to sustainability, digitalization, and innovation.
Gülçinay Mumcu, Steven A. Brieger
wiley +1 more source
Seats at the Table, Shifts in the Actions: Board Gender Diversity and Climate Activism
Corporate Social Responsibility and Environmental Management, EarlyView.ABSTRACT As regulatory and stakeholder pressures intensify, firms are increasingly expected to move beyond symbolic sustainability commitments towards corporate climate activism. This concept refers to the active institutionalisation of climate‐focused mechanisms such as external assurance, board oversight and climate‐linked incentives.
Md Tanvir Hamim, Rasim Simsek
wiley +1 more source